Receptor for advanced glycation endproducts controls deleterious lung inflammation in severe Pseudomonas aeruginosa pneumonia in immunosuppressed mice 英文参考文献.docVIP

下载本文档

7
0
约32.67万字
约 58页
2017-05-13 发布于上海
举报
版权申诉

Receptor for advanced glycation endproducts controls deleterious lung inflammation in severe Pseudomonas aeruginosa pneumonia in immunosuppressed mice 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Receptor for advanced glycation endproducts controls deleterious lung inflammation in severe Pseudomonas aeruginosa pneumonia in immunosuppressed mice 英文参考文献

CriticalCare2012,Volume16Suppl3 /supplements/16/S3 MEETING ABSTRACTS OpenAccess Sepsis2012 Paris,France.7-9November2012 Published:14November2012 Theseabstractsareavailableonlineat/supplements/16/S3 POSTER PRESENTATIONS mechanismsinindividualpatientswithsepsisprogressionacrosssepsisto septicshock. P1 Modelingsepsisusingneuralnetsandbiomarkersoforgan dysfunctioninpatients,withlinkstoanimalmodels P2 1* JSchentag ,DParish2,SOpal 3 Extracellular matrix turnover, angiogenesis andendothelial function inacute lunginjury: relationship topulmonary dysfunction and outcome SSayed*,NIdriss,HSayyed 1UniversityatBuffalo,Buffalo,NY,USA; 2CPLAssociatesLLC,Buffalo,NY,USA; 3BrownUniversity,Providence,RI,USA CriticalCare2012,16(Suppl3):P1 FacultyofMedicine,AssuitUniversity,Assuit,Egypt E-mail:1@ CriticalCare2012,16(Suppl3):P2 Background: Mostclinicaltrialsofsepsistreatmentmodalitiesfailattheir primaryobjectiveofestablishingsuperiorityoverplacebowhenaddedto background standard ofcare.Whilethereisnodefinitive explanation for thehighfailurerate,itmightbestatedthatourattemptstoinsertanew therapeuticagentintostandardofcareencounterssevereproblemswith definition ofexactly whatstageisongoing, andwhatarethecriteria for progression orresolution from that time point onwards. Clearly there is needforameansofdefiningstepsinthesepticprocessthatwouldapply toindividuals, and tobetter define thecourse ofsepsis ineach patient aftertheyareenrolledinatrial. Methods: For core modeldevelopment, 30septic patients were studied fortime-related progression inrelation tobiomarkers, employing aLoad ModelinaneuralnetalgorithminMatLab.Causativebacterial infections were linked to primary infection sites. In order to minimize over- parameterization, the model was allowed to estimate outputs using the bestthreeinputparameters.Bacterialloadwastrackedfromoriginusing clinical and microbiologic data to provide an estimate at the start of sepsis. The bacterial load as well as clinical and laboratory pa